Market news

On August 11, Autolus Therapeutics (NASDAQ:AUTL) reported second-quarter results that finally showed the kind of growth investors had been waiting years to see. Net product revenue hit $45.7 million, up 119% from $20.9 million a year earlier and up from $26.2 million just one quarter prior. Management used the momentum to raise full-year 2026 guidance […]

Tipranks Press Release.

Motley Fool Press Release.

Detailed price information for Autolus Therapeutics Plc ADR (AUTL-Q) from The Globe and Mail including charting and trades.

Detailed price information for Autolus Therapeutics Plc ADR (AUTL-Q) from The Globe and Mail including charting and trades.

Detailed price information for Autolus Therapeutics Plc ADR (AUTL-Q) from The Globe and Mail including charting and trades.

Detailed price information for Cronos Group Inc (CRON-Q) from The Globe and Mail including charting and trades.

Autolus Therapeutics plc (NASDAQ:AUTL) shares rose 3. 19% in pre-market trading on Tuesday after the biotechnology company delivered better-than-expected second-quarter results and raised its full-year revenue guidance for AUCATZYL.

Autolus Therapeutics (NASDAQ:AUTL) reported second-quarter 2026 net product revenue of $45.7 million from sales of AUCATZYL, up from $26.2 million in the first quarter and $20.9 million a year earlier, as the company expanded treatment-center access and continued its commercial launch in the United

Autolus reports second quarter 2026 financial results and business updates....

Detailed price information for Autolus Therapeutics Plc ADR (AUTL-Q) from The Globe and Mail including charting and trades.

Detailed price information for Autolus Therapeutics Plc ADR (AUTL-Q) from The Globe and Mail including charting and trades.

Detailed price information for Unitedhealth Group (UNH-N) from The Globe and Mail including charting and trades.

Dow Jones index gained 600 points, CNH Industrial rose 16% after reporting better-than-expected Q2 results, other stocks also recording gains.

LONDON and GAITHERSBURG, Md., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that the Company will release its second quarter 2026 financial results and operational highlights before open of U.S. markets on Tuesday, August 11, 2026. Management will host a conference call and webcast at 8:30am EDT / 1:30pm BST to discuss the

Company reports preliminary Q2 2026 AUCATZYL net product revenue of approximately $45 million and gross margin of approximately 35% year-to-date FY 2026 sales guidance increased to $140 – $150 million, from $120 – $135 millionCapital base strengthened through five-year, interest-only credit facility with $75 million funded at closeAutolus to report Q2 2026 financial results on August 11, 2026 LONDON and GAITHERSBURG, Md., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL),

Autolus Therapeutics plc (NASDAQ:AUTL) is one of the 10 Fastest Growing Tech Penny Stocks to Buy. On July 1, 2026, Autolus Therapeutics plc (NASDAQ:AUTL) announced that the Compensation Committee of its Board of Directors granted stock option awards to purchase an aggregate of 25,420 American Depositary Shares and 87,530 restricted stock units to 13 employees […]